adult pattern is established. If in the adult the pituitary is removed the 17-oxosteroid response to ACTH returns to that characteristic of the prepubertal child. In women with hirsutism which is not due to a tumour of the adrenal or ovary the 1 7-oxosteroid response to ACTH is usually greater than normal. The same applies to some men who have lost their Leydig cell function. The reverse is true in patients with delayed puberty and women with testosterone-secreting tumours. These facts suggest that the adrenal precursors of urinary 1 7-oxosteroids are controlled by a hormone other than ACTH and that there is integration in the overall production of some precursors from both adrenal and gonad. There is suggestive evidence that the human pituitary contains a factor which potentiates adrenal 17-oxosteroid synthesis. Adrenal morphology and vasculature were studied by reconstruction models, microangiography and electron microscopy. The adrenal can be divided into head, body and tail regions. In each region the characteristic longitudinal muscle bundles of the venous system have distinct arrangements. Emissary veins linking the central and capsular venous system provide an alternative route for the venous effluent. Electron microscopy reveals variations in mitochondria, lipid (which may be free or membrane-bound), endoplasmic reticulum and lysosome-like particles. The complex cortical vasculature may be of significance in controlling the rate of ACTH presentation in the interface zone to certain cells which show special ultrastructural features. Results of our early experiments with adrenal glands from human subjects suggested that natural corticotrophin of bovine origin, in vitro, influences the amount of secretion of steroids from the cells of the zona fasciculata to a greater extent than that from other cells. Further investigations suggested that cells lying in the border between the fascicular and reticular zones are particularly sensitive to this corticotrophin administered in vivo. Of four NADP-linked dehydrogenases in the adrenal cortex studied in vitro, only glucose-6-phosphate dehydrogenase showed a marked increase in amount or activity after corticotrophin administration in vivo. The increase does not parallel the concomitant increase in weight of the gland. The enzyme activity is distributed uniformly in the 'resting' gland but, after corticotrophin administration, shows a marked increase in the same 'border zone'. By application of the more refined microchemical techniques of Glick, we have further shown a similar regional distribution of increased steroid 11 ,-hydroxylation in response to corticotrophin in the adrenal cortex of the rat. It is an open question whether increases in RNA which follow corticotrophin administration are associated with steroid production per se or tissue hyperplasia or both. Our results offer some evidence that at some stage at least the two processes may not be associated.
In recent experiments, the effect on the adrenal cortex of the synthetic 31-24 ACTH (Synacthen) has been studied. Synacthen was administered prior to the second stage of bilateral adrenalectomy. The patients, women with carcinoma of the breast, had previously had pituitary function destroyed by yttrium implants. Satisfactory adrenal gland growth observed with the synthetic corticotrophin suggests that postulation of a separate adrenal growth factor is unnecessary.
Steroid biosynthesis has been investigated in vitro in greater detail than formerly, using the severely atrophic and Synacthen-stimulated adrenal glands from the hypophysectomized patients. The results confirm and extend our earlier findings. The steroidogenic properties of two derivatives of P-corticotrophin-(1-24)-tetracosa peptide (tetracosactide), namely D-Serl, 3l-24-corticotrophin and D-Serl, 17, 18-di-orn-f3-24-corticotrophin, have been investigated in comparison with tetracosactide. The melanophore-expanding properties of the three substances have also been studied in vitro using frog skins. Steroidogenesis in vitro was measured by the adrenal incubation method; the increase in the plasma corticosterone concentration in hypophysectomized rats was employed as an in vivo parameter. Compared with tetracosactide, both derivatives were found to display more potent melanophore-expanding properties in vitro on a weight-for-weight basis. Evaluated by reference to steroidogenesis in vitro, only D-Ser1, 17, 18-di-om-P31-24-corticotrophin shows greater activity than tetracosactide. With respect to steroidogenesis in vivo, however, both derivatives are more potent than tetracosactide on a weightfor-weight basis, the D-Serl, 17, 18-di-orn-1l-24corticotrophin displaying about ten times the activity of tetracosactide. In addition, when the two derivatives are injected in large doses, they do not produce higher plasma corticosterone concentrations than tetracosactide, but they do exert a more prolonged duration of action, which is equivalent in the one case to about three times and, in the other case, to more than four times that of tetracosactide. Administration of pharmacological amounts of dexamethasone results in rapid and complete cessation of cortisol secretion which can be demonstrated by following the changes in the specific activity of plasma cortisol if 14C-cortisol is given prior to the infusion of dexamethasone. The corollary that this implies total cessation of ACTH secretion requires the additional demonstration that dexamethasone has no direct action on the adrenal cortex.
Single injectionw of synthetic porcine or 1-24 ACTH will increase plasma cortisol, and threshold sensitivity in control subjects lies within the range of 62-5 to 250 ng of peptide. This response remains unaltered when dexamethasone is infused, thus demonstrating the lack of any direct effect of this compound on the adrenal cortex.
Amounts of cortisol within the physiological range (up to 20 mg/day) can be administered by constant infusion without significantly increasing either blood steroid levels or urinary 17-hydroxycorticosteroids. This is put forward as evidence to support the view that a physiological feed-back system operates in man in which plasma cortisol and ACTH secretion bear a reciprocal relationship. This feed-back mechanism appears to be bypassed in a number of situations (hypoglycemia, pyrogen administration, emotional disturbances) in which ACTH release occurs independently of the existing blood cortisol levels. In the majority of cases, dexamethasone fails to block this response. Lysine-8-vasopressin (LVP) also causes ACTH release and it has been suggested that it acts directly on the anterior pituitary. The effect is completely blocked by synthetic steroids and this finding accords better with the view that LVP acts at hypothalamic level. Vasopressin stimulates the release of ACTH in animals and man. Extensive bilateral lesions in the median eminence of the hypothalamus, which inhibit the release of ACTH following stress, reduce the corticotrophic effect of lysine vasopressin. This reduction is more marked in rats bearing lesions in the pituitary stalk and adjacent areas. This difference may be explained by the extent of portal vessel system damage or by blockade of nonspecific effects of vasopressin on ACTH release whereby the remaining effect may be regarded as a specific corticotrophin-releasing action.
ACTH content of the pituitary of intact rats or rats with an extensive lesion in the median eminence, injected intravenously with 200 mU of lysine vasopressin, is not depleted during the time of maximal ACTH release, indicating that vasopressin stimulates synthesis as well as release of ACTH at the level of the pituitary.
Blockade ofthe hypothalamic-pituitary-adrenal system with pharmacological agents such as chlorpromazine or a.-ethyl tryptamine may also reduce the corticotrophic effect of vasopressin. A relatively small lesion in the anterior median eminence of the hypothalamus counteracts the reduced response to vasopressin in rats treated with high doses of chlorpromazine for approximately 12 hours, suggesting the dependence on the hypothalamus for vasopressin-induced ACTH release.
The rise in blood pressure by vasopressin is markedly potentiated in rats anasthetized with
